

AMRL-TR-65-135

AD 622321  
citation

## SCREENING OF NEW CHELATING AGENTS FOR BERYLLIUM

WOLFGANG STERNER  
L. E. LOVELESS

INTERNATIONAL BIO-RESEARCH, INC.

AUGUST 1965

20060711018

STINFO COPY

AEROSPACE MEDICAL RESEARCH LABORATORIES  
AEROSPACE MEDICAL DIVISION  
AIR FORCE SYSTEMS COMMAND  
WRIGHT-PATTERSON AIR FORCE BASE, OHIO

## NOTICES

When US Government drawings, specifications, or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data, is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Requests for copies of this report should be directed to either of the addressees listed below, as applicable:

Federal Government agencies and their contractors registered  
with Defense Documentation Center (DDC):

DDC  
Cameron Station  
Alexandria, Virginia 22314

Non-DDC users (stock quantities are available for sale from):

Chief, Input Section  
Clearinghouse for Federal Scientific & Technical Information (CFSTI)  
Sills Building  
5285 Port Royal Road  
Springfield, Virginia 22151

### Change of Address

Organizations and individuals receiving reports via the Aerospace Medical Research Laboratories automatic mailing lists should submit the addressograph plate stamp on the report envelope or refer to the code number when corresponding about change of address or cancellation.

Do not return this copy. Retain or destroy.

The experiments reported herein were conducted according to the "Principles of Laboratory Animal Care" established by the National Society for Medical Research.

# **SCREENING OF NEW CHELATING AGENTS FOR BERYLLIUM**

*WOLFGANG STERNER  
L. E. LOVELESS*

## FOREWORD

This study was initiated by the Biomedical Laboratory of the Aerospace Medical Research Laboratories, Aerospace Medical Division, Wright-Patterson Air Force Base, Ohio. The research was performed in support of Project No. 6302, "Toxic Hazards of Propellants and Materials," and Task No. 630202, "Pharmacology and Biochemistry," under Contract No. AF 33(615)-1804 with International Bio-Research, Inc, St Louis, Missouri. Dr med vet Wolfgang Sterner was the principal investigator for International Bio-Research, Inc., and Mr. Leandro Rendon was contract monitor for the Toxic Hazards Branch, Physiology Division. Research was initiated June 1964 and completed March 1965.

The technical assistance of H. Kramer, DVM, and Erika Sterner, Medical Technologist, in the conduct of this work is greatly appreciated.

This technical report has been reviewed and is approved.

WAYNE H. McCANDLESS  
Technical Director  
Biomedical Laboratory

## ABSTRACT

Thirteen polyaminopolycarboxylic acid chelating agents were evaluated in vitro and in vivo as potential therapeutic agents for acute beryllium poisoning. In the in vitro test system the ability of the chelating agent to reverse beryllium induced inhibition of alkaline phosphate was measured. In the in vivo system, the chelating agent was evaluated by its ability to prevent mortality of rats that had received an acute lethal dose (LD<sub>50</sub>) of beryllium sulfate. None of the polyaminopolycarboxylic acids reversed completely the inhibition of alkaline phosphatase at either 35 percent or 65 percent levels of inhibition. All compounds were ineffective in overcoming the toxic dose of beryllium in rats.

## TABLE OF CONTENTS

### SECTION

I. INTRODUCTION . . . . .	1
II. MATERIALS AND METHODS. . . . .	1
Test Materials . . . . .	1
Test Animals . . . . .	2
Test Methods . . . . .	2
III. EXPERIMENTAL RESULTS . . . . .	3
In vitro Inhibition of Alkaline Phosphatase by Beryllium . . . . .	3
Acute Intravenous Toxicity of Beryllium. . . . .	9
Acute Toxicity of Polyaminopolycarboxylic Acids. . . . .	9
Therapeutic Effects of Polyaminopolycarboxylic Acids in Beryllium Poisoning . . . . .	10
IV. CONCLUSIONS . . . . .	21

# LIST OF TABLES

<u>TABLE</u>	<u>PAGE</u>
I. Effect of Beryllium on Plasma Alkaline Phosphatase Activity of Rats . . . . .	4
II. Effects of Various Chelating Agents on the In Vitro Activity of Rat Plasma Alkaline Phosphatase. . . . .	6
III. Effects of Various Chelating Agents on the Beryllium Induced Inhibition of Rat Plasma Alkaline Phosphatase. . . . .	7
IV. Effect of Polyaminopolycarboxylic Acids on Beryllium Inhibition of Alkaline Phosphatase . . . . .	8
V. Mortality of Male Rats Receiving an Acute Intravenous Dose of Beryllium Sulfate. . . . .	12
VI. Summary of LD50 Assay of Beryllium. . . . .	13
VII. Acute Intraperitoneal Toxicities of Various Chelating Agents . . . . .	14
VIII. Mortality of Male Rats Receiving Chelating Agents Following Acutely Toxic Doses of Beryllium . . . . .	18
IX. Weight Gain of Male Rats Receiving Chelating Agents Following Acutely Toxic Doses of Beryllium . . . . .	20

## SECTION I

### INTRODUCTION

The effectiveness of aurintricarboxylic acid (ATA) in the treatment of acute beryllium poisoning in mice and rats has been described by investigators at Argonne National Laboratory (ref 1, 2). These same investigators demonstrated that ATA reverses the inhibition of rat plasma alkaline phosphatase by beryllium (ref 3).

This study was undertaken to determine (a) whether reversal of the beryllium-induced inhibition of rat plasma alkaline phosphatase might serve as a reliable screening test to disclose compounds that might be useful in the treatment of acute beryllium intoxication and (b) to evaluate a group of polyaminopolycarboxylic acids for effectiveness in counteracting in vitro and in vivo the toxic manifestations of beryllium.

## SECTION II

### METHODS AND MATERIALS

#### TEST MATERIALS

Beryllium sulfate tetrahydrate ( $\text{BeSO}_4 \cdot 4\text{H}_2\text{O}$ ) was obtained from Fisher Scientific Company. The in vitro results obtained with this source of beryllium were compared with those using a sample of the same  $\text{BeSO}_4 \cdot 4\text{H}_2\text{O}$  (C. P. Eimer & Amend) that was used in the studies of Lindenbaum et al (ref 3). No significant differences could be detected between these two beryllium sources with respect to their effect on alkaline phosphatase activity. Aurintricarboxylic acid (ATA) was obtained from Fisher Chemical Company (A546 Reagent Grade, ammonium salt). Salicylic acid (SA) was obtained from Matheson, Coleman & Bell (CB 748, as sodium salt).

The polyaminopolycarboxylic acids were obtained through the curtesy of Dr. Murray Weiner, Geigy Chemical Corporation, Ardsley, New York. These compounds were available only in small amounts (2 to 5 g each). These acids are coded as follows:

ATA . . . . .	Aurintricarboxylic acid
SA . . . . .	Salicylic acid
EDTA . . . . .	Ethylenediamine-NNN'N'-tetraacetic acid
DAEE TA . . . . .	$\beta, \beta$ -diaminoethylether-NNN'N'-tetraacetic acid
DET PA . . . . .	Diethylenetriamine-NNN'N'N''-pentaacetic acid
TET HA . . . . .	Triethylenetetramine-NNN'N'N'N''-hexaacetic acid
EG(AEE) TA . . . . .	Ethyleneglycol-bis( $\beta$ -aminoethylether)-NNN'N'-tetraacetic acid
(HCH)ED TriA . . . . .	N'-(2-Hydroxycyclohexyl)ethylenediamine-N'NN-triacetic acid
(AE)CHA TA . . . . .	2-( $\beta$ -Aminoethoxy)-cyclohexylamine-NNN'N'-tetraacetic acid
(DCMACH)ED TriA . . . . .	N-[(2-Dicarboxymethylamino)cyclohexyl]-ethylenediamine-NN'N'-triacetic acid
PG(AEE) TA . . . . .	1,2-Propyleneglycol-bis-( $\beta$ -aminoethylether)-NNN'N'-tetraacetic acid
2,3-BG(AEE) TA . . . . .	2,3-Butyleneglycol-bis-( $\beta$ -aminoethylether)-NNN'N'-tetraacetic acid
1,4-BG(AEE) TA . . . . .	1,4-Butyleneglycol-bis-( $\beta$ -aminoethylether)-NNN'N'-tetraacetic acid



TATEA HA . . . . . 888'''-Triaminotriethylamine-NNN'N'N'N'N'N'N'-hexaacetic acid  
TEPA HA . . . . . Tetraethylenepentaamine-NNN'N'N'N'N'N'N'N'N'N'-heptaacetic acid

## TEST ANIMALS

Sprague-Dawley rats were used throughout the study. Female animals weighing approximately 250 g each were used as sources of blood in the in vitro portions of the study. Male rats exclusively were used for the in vivo portions of the study, to avoid complications that might result from interactions between strong chelating agents, inorganic ions, and endocrine functions.

## TEST METHODS

### Alkaline Phosphatase Determinations

The activity of plasma alkaline phosphatase was measured by the method of Bodansky (ref 4) as modified by DuBois et al (ref 5). This test system involved the incubation of 0.1 ml of plasma from freshly drawn cardiac blood with 1.0 ml of 0.025 M Veronal buffer (pH 8.9) containing 0.015 M sodium  $\beta$ -glycerophosphate and water (or beryllium sulfate and test solutions) to make a final volume of 1.7 ml. After incubation at 38° C for 30 minutes, the reaction was stopped by the addition of 0.3 ml of 50% trichloroacetic acid. After centrifugation, the inorganic phosphate was measured by the method of Fiske and SubbaRow (ref 6).

The inhibition of alkaline phosphatase by beryllium was studied at beryllium concentrations that provided approximately 35 percent and 65 percent inhibition. Reversal of the beryllium-induced inhibition was determined by addition to the in vitro system of a tenfold and twentyfold molar excess of the test compound relative to beryllium. From the measured activity of the enzyme in the presence of both beryllium and the test compound, the percent reversal of the beryllium inhibition was calculated from the formula:

$$100 \left\{ 1 - \frac{\% \text{ observed inhibition}}{\% \text{ inhibition of Be Control}} \right\}$$

Thus, at a beryllium concentration of  $4 \times 10^{-6}$  M, which produced a 37 percent inhibition of alkaline phosphatase activity, the test chemicals were added to the test system at  $4 \times 10^{-5}$  M and  $8 \times 10^{-5}$  M, a tenfold and twentyfold molar excess, respectively. At beryllium concentrations of  $10^{-5}$  M, which produced a 65 percent inhibition of enzyme activity, test compounds were evaluated at  $10^{-4}$  M and at  $2 \times 10^{-4}$  M (ref 2).

### In vivo Toxicity

Animals were individually caged on wood shavings with a standard laboratory ration and water available ad libitum. The animal room was maintained at 23° C and a relative humidity of 50% to 60%. Animals were fasted for 16 hours before administration of the chemicals.

Beryllium sulfate was administered intravenously as a sterile aqueous solution in the tail vein. Injection time in all cases was approximately 15 seconds.

Either aqueous solutions of polyaminopolycarboxylic acids or their solutions after neutralization with equimolar solution of calcium-sodium hydroxide were administered by intraperitoneal injection within 5 minutes after injection of the beryllium sulfate solution.

Two test compounds were administered orally by stomach tube in addition to the intraperitoneal injection.

Data were treated by the method of Litchfield and Wilcoxon to determine the acute toxicities and slopes of mortality curves (ref 7).

### SECTION III

#### EXPERIMENTAL RESULTS

##### IN VITRO INHIBITION OF ALKALINE PHOSPHATASE ACTIVITY BY BERYLLIUM

The alkaline phosphatase activity of rat plasma was found to be 0.34 units (1 unit = 1 mg P release per gram of tissue or plasma per hour). This value agrees with that observed by DuBois et al (ref 5).

The molar concentration response curve of beryllium on this in vitro system (table I, figure 1) reveals that  $6.0 \times 10^{-6}$  M  $\text{Be}^{++}$  is required to produce 50 percent inhibition of alkaline phosphatase. This value is approximately 3 times that reported by DuBois (ref 5) and that obtained by extrapolation of the data of Lindenbaum (ref 3). The curve, however, is quite steep, which indicates that relatively small changes in concentration can cause large differences in response. In the test system reported here, a concentration of  $3.5 \times 10^{-6}$  M of  $\text{Be}^{++}$  appeared to be the 35-percent inhibition concentration while  $1.0 \times 10^{-5}$  M was the 65% inhibition value.

A number of the polyaminopolycarboxylic acids were themselves inhibitors of rat plasma alkaline phosphatase. EDTA, DAEE TA, (DCMACH)ED TriA, PG(AEE) TA, TATEA HA, and TEPA HA all significantly inhibited alkaline phosphatase activity in the concentration range of interest (table II).

The effects of the various chelating agents on beryllium-induced inhibition of alkaline phosphatase are presented in table 3 and summarized in table 4. With the exception of ATA and SA none of the chelating agents was remarkable in its ability to reverse the inhibition by beryllium. DAEE TA, (AE)CHA TA, and TEPA HA were the superior agents in this test. Even in the absence of beryllium each of these agents at the molar concentrations required to provide a tenfold to twentyfold excess of beryllium inhibited the activity of alkaline phosphatase by ten to twenty percent (table II). Since the observed inhibition of enzyme activity in the in vitro system might be an additive, combined inhibition effect of the test chemical and beryllium, it was possible that the in vivo activity of these compounds in reversing beryllium toxicity might be greater than the in vitro data indicated.

TABLE I  
EFFECT OF BERYLLIUM ON PLASMA ALKALINE  
PHOSPHATASE ACTIVITY OF RATS

<u>Molar Concentration of Be<sup>++</sup></u>	<u>Percent Inhibition of Alkaline Phosphatase</u>	
	<u>Observed</u>	<u>No. of detm.</u>
1 x 10 <sup>-6</sup>	9	3
2 x 10 <sup>-6</sup>	27	6
3 x 10 <sup>-6</sup>	30	3
4 x 10 <sup>-6</sup>	37	2
5 x 10 <sup>-6</sup>	40	8
6 x 10 <sup>-6</sup>	50	3
1 x 10 <sup>-5</sup>	64	7
2 x 10 <sup>-5</sup>	77	6
4 x 10 <sup>-5</sup>	85	1
5 x 10 <sup>-5</sup>	87	1
6 x 10 <sup>-5</sup>	92	1

Observed activity of alkaline phosphatase in fresh rat plasma = 0.34 mg P/ml/hour




TABLE II

EFFECTS OF VARIOUS CHELATING AGENTS  
ON THE IN VITRO ACTIVITY OF RAT PLASMA  
ALKALINE PHOSPHATASE

Chelating Agent	Alkaline Phosphatase Activity (% of Control) at		
	<u><math>1 \times 10^{-4}</math> M</u>	<u><math>5 \times 10^{-5}</math> M</u>	<u><math>2 \times 10^{-5}</math> M</u>
ATA	104	108	100
SA	97	100	99
EDTA	82	88	94
DAEE TA	80	101	106
DETPA	90	96	103
TET HA	94	92	100
EG(AEE) TA	104	97	100
(HCH)ED TriA	115	115	112
(AE)CHA TA	90	97	100
(DCMACH)ED TriA	82	97	101
PG(AEE) TA	74	83	90
2,3 - BG(AEE) TA	97	95	101
1,4 - BG(AEE) TA	99	97	100
TATEA HA	81	90	100
TEPA HA	83	88	92
<hr/>			
Control: 0.31 units			
<hr/>			

TABLE III  
EFFECTS OF VARIOUS CHELATING AGENTS ON  
THE BERYLLIUM INDUCED INHIBITION OF  
RAT PLASMA ALKALINE PHOSPHATASE

Chelating Agent	% Reversal of Alkaline Phosphatase Inhibition			
	$3 \times 10^{-6}$ M Be <sup>++</sup>		$1 \times 10^{-5}$ M Be <sup>++</sup>	
	Chelate at Molar Excess of 10 x	20 x	Chelate at Molar Excess of 10 x	20 x
ATA	72	90	98	113
SA	42	70	76	88
EDTA	26	-4	3	3
DAEE TA	6	37	28	44
DET PA	2	-7	10	6
TET HA	24	-6	18	13
EG(AEE) TA	0	-8	5	4
(HCH)ED TriA	6	-8	14	13
(AE)CHA TA	78	11	19	26
(DCMACH)ED TriA	-6	6	20	36
PG(AEE) TA	13	31	-10	2
2,3 - BG(AEE) TA	9	20	-4	11
1,4 - BG(AEE) TA	22	49	-2	0
TATEA HA	31	22	-6	16
TEPA HA	24	57	28	12

TABLE IV

EFFECT OF POLYAMINOPOLYCARBOXYLIC ACIDS ON  
BERYLLIUM INHIBITION OF ALKALINE PHOSPHATASE

Chelating Agent	Mean of % Reversal of Inhibition at		% Reversal of Inhibition by Chelate Excess of	
	$3 \times 10^{-6}$ M Be <sup>++</sup>	$1 \times 10^{-5}$ M Be <sup>++</sup>	10 fold	20 fold
ATA	81	106	85	102
SA	56	82	59	79
EDTA	11	3	14	0
DAEE TA	22	36	17	40
DETPA	-2	8	6	0
TET HA	9	16	21	4
EG(AEE) TA	-4	4	2	-2
(HCH)ED TriA	-1	14	10	2
(AE)CHA TA	44	22	48	18
(DCMACH)ED TriA	0	28	7	21
PG(AEE) TA	22*	-4	2	16
2,3-BG(AEE) TA	14*	4	2	16
1,4-BG(AEE) TA	36*	-1	10	24
TATEA HA	26*	5	12	19
TEPA HA	40*	20	26	34

\*  $4 \times 10^{-6}$  M Beryllium

## ACUTE INTRAVENOUS TOXICITY OF BERYLLIUM

### Mortality

The mortality of male rats receiving intravenous injections of beryllium sulfate is presented in table V. Most animals died within 48 hours. Practically all, even at the 0.5 mg of  $\text{Be}^{++}/\text{kg}$  dose died within 14 days.

### Clinical Appearance

During injection the animals appeared unduly agitated, as evidenced by squealing and struggling. Some immediately went into deep coma-like depression, resting on side position, with intermittent respiratory arrest and spasmodic breathing. After 5 to 8 minutes, however, most of the animals exhibited normal behavior, although a few were slightly depressed. After 2 days post-treatment the survivors became acutely ill and were in deep depression. Food intake was practically nil. Most of the survivors showed yellowish discoloration of the ears, legs and tails, indicative of jaundice.

### Gross Necropsy

Even at the lowest dose (0.35 mg  $\text{Be}^{++}/\text{kg}$ ) most of the animals exhibited a yellowish discoloration of the liver. In a number of cases, livers were swollen and spleens were enlarged.

At dosages of 0.51 mg  $\text{Be}^{++}/\text{kg}$  and higher, the same pathologic alterations were noted although jaundice was more pronounced. In addition, there were petechial hemorrhages in various organs: lungs, thymus, intestines and lymph nodes.

In the (10.2 mg  $\text{Be}^{++}/\text{kg}$ ) and higher dose groups, additional necropsy findings included pronounced fluid accumulation in the chest cavity (hydrothorax).

### LD<sub>50</sub> Calculations

The mortality data of rats receiving beryllium are plotted in figure 2 and summarized in table V. The 14-day LD<sub>50</sub> and LD<sub>95</sub> calculations (ref 7) (see table VI herein) are 0.46 and 1.0 mg  $\text{Be}^{++}/\text{kg}$ , respectively. The LD<sub>50</sub> value for rats compares with that reported by Aldridge et al (ref 8) (0.53 mg/kg, intravenous) and Cochran et al (ref 9) (0.56 mg/kg intraperitoneal). The LD<sub>95</sub> value is more than that of 0.7 mg/kg reported by Lindenbaum et al (ref 2).

The 48-hour LD<sub>50</sub> of beryllium was 2.6 mg/kg (1.5 to 4.6 mg/kg) while the 48-hour LD<sub>95</sub> was 14.5 mg/kg (6 to 36 mg/kg). Test compounds were evaluated at both the 48-hour LD<sub>95</sub> of beryllium and at the 0.7 mg/kg dose, reported by Lindenbaum which is, in these experiments, a 14-day LD<sub>93</sub> acute toxicity.

## ACUTE TOXICITY OF POLYAMINOPOLYCARBOXYLIC ACIDS

The available amounts of test chemicals were quite limited (2 to 5 g each). Hence, only a limited number of animals were used to determine the intraperitoneal toxicity of each compound. The results of these experiments are presented in table 7. From these data an estimate was made of the Maximum Tolerated Dose (MTD). In some cases inadequate amounts of the test chemical were available to use the MTD. In those cases doses approaching the maximum



tolerated dose, commensurate with the available amount of chelating agent on hand, were administered. In cases in which all of the rangefinding doses produced some pharmacological effects estimates of the MTD were made. Such estimates were based upon the doses causing mortality and/or other clinical symptoms and frequently represent 0.4 log interval of the lethal dose. In practically all cases, the MTD's for the free acids and the sodium-calcium salts were equivalent.

#### THERAPEUTIC EFFECTS OF POLYAMINOCARBOXYLIC ACIDS IN BERYLLIUM POISONING

The mortality data presented in table 8 show that none of the compounds was remarkably effective in preventing the toxic effects of beryllium. ATA which reduced the toxicity of  $\text{Be}^{++}$  from 90% to 55% was the most effective; this effectiveness was achieved only by intraperitoneal administration of the ATA; oral administration of ATA was ineffective.

SA at 200 mg/kg, DET PA at 300 mg/kg, TATEA HA at 200 mg/kg, and TEPA HA at 400 mg/kg, when administered intraperitoneally, reduced the mortality of 0.71 mg/kg of  $\text{Be}^{++}$  from 90% to 70%. With the limited amount of test chemical and the limited number of animals per group, it could not be determined whether this reduction in mortality was significant.

None of the compounds was effective against 10 mg of  $\text{Be}^{++}$ /kg. Necropsy of all animals revealed the same gross pathological findings as the "untreated" beryllium control groups.

The results of this study indicate that the polyaminopolycarboxylic acids are rather ineffectual in preventing beryllium-induced mortality. Three compounds, (AE)CHA TA, TATEA HA, and TEPA HA, reduced mortality to about 70% as compared to 90% mortality with no chelating agent. With the exception of (AE)CHA TA in which 20 animals received 400 mg/kg, the reduction of mortality by 2 animals per dose group is of questionable significance. These findings are consistent with the hypothesis of Schubert (ref 10) that compounds, in order to be effective against beryllium, must possess an ortho hydroxy carboxyl structure. ATA and SA both have such structures. The hydroxy and glycol polyaminopolycarboxy acids were ineffective in this study.




TABLE V  
MORTALITY OF MALE RATS RECEIVING AN ACUTE INTRAVENOUS  
DOSE OF BERYLLIUM SULFATE

Dose (mg/kg)		Range of Body Weights (g)		Mortality at Time (days post injection)									Total	
<u>BeSO<sub>4</sub>·4H<sub>2</sub>O</u>	<u>Be<sup>++</sup></u>	<u>Initial</u>	<u>Final</u>	<u>0-1</u>	<u>1-2</u>	<u>2-3</u>	<u>3-4</u>	<u>4-5</u>	<u>5-6</u>	<u>6-7</u>	<u>7-14</u>		<u>No.</u>	<u>%</u>
6.9	0.35*	116 ± 13	130 ± 12		1					1			2/10	20
9.8	0.50*	118 ± 16	121 ± 4					5		2			7/10	70
14	0.71*	116 ± 15	135				24	18	12				54/60	90
20	1.0 *	114 ± 12	122	1	4	2	2						9/10	90
20	1.0	114 ± 16	128 ± 3	1	4	2	1						8/10	80
40	2.0	116 ± 16	106 ± 4		4	3	1						8/10	80
80	4.1	119 ± 19			7	3							10/10	100
160	8.1	121 ± 12		4	4	2							10/10	100
200	10.2	120 ± 13		4	6								10/10	100
252	12.8	119 ± 14		6	4								10/10	100
318	16.2	120 ± 13		5	5								10/10	100
0	0	123 ± 10	159 ± 11											

\* Second Study

TABLE VI

SUMMARY OF LD<sub>50</sub> ASSAY OF BERYLLIUM

Dosage: 0.35 to 1.0 mg Be<sup>++</sup>/kg (6.9 to 20 mg BeSO<sub>4</sub>·4H<sub>2</sub>O/kg)

Test Chemical: BeSO<sub>4</sub>·4H<sub>2</sub>O

Concentration: 1% - 3% in sterile distilled water; approximately 0.1 ml per animal

Animals: Fasted male Sprague-Dawley Rats (100 - 130 g each)

Route of Administration: Intravenous

Symptoms: During injection, animals became unduly agitated. Many animals went into deep depression immediately after injection, with intermittent respiratory arrest and spasmodic breathing; after 5 to 8 minutes, animals acted clinically normal for 24 to 48 hours. Mortalities occurred after 24 to 48 hours in deep depression. Many animals showed signs of jaundice. Necropsy showed enlarged yellow livers, enlarged spleen and jaundice.

	<u>14 days</u>
LD <sub>50</sub> Be <sup>++</sup> (mg/kg) + 95% Confidence Limits	0.46 (0.39 - 0.53)
Slope Function-Slope + 95% Confidence Limits	1.64 (1.28 - 2.10)
LD <sub>95</sub> Be <sup>++</sup> (mg/kg) + 95% Confidence Limits	1.0 (0.61 - 1.65)

TABLE VII

## ACUTE INTRAPERITONEAL TOXICITIES OF VARIOUS CHELATING AGENTS

Test Compound	Dose (mg/kg)	Mortality (No. dead /total)	FINDINGS	Estimated Maximum Tolerated Dose (MTD) (mg/kg)
ATA	207	0/2	Moderate depression for several hours.	150
	261	0/2	Moderate depression for several hours.	
	395	2/2	Deep depression; death within 12 to 24 hours.	
	500	2/2	Deep depression; death after 18 hours, necropsy revealed various amounts of free blood and coagulated blood in the abdominal cavity of most animals.	
SA	50*	0/2	No clinical or pathological symptoms.	200
	100*	0/2	No clinical or pathological symptoms.	
	200*	0/2	No clinical or pathological symptoms.	
	400	2/2	At all levels greater than 200 mg/kg, staggering gait, some animals tonic-clonic convulsions; death after 12 to 16 hours	
	792	2/2	(400 mg/kg), 1 to 2 hours (792 mg/kg), 3 to 6 minutes (1000 mg/kg); necropsy showed whitish discoloration of abdominal cavity content.	
EDTA	250	0/2	No clinical or pathological findings.	250
	500	1/1	Depression; tonic-clonic convulsions and death.	
	1000	1/1	Death within 25 minutes; no gross pathological lesions.	
DAEE TA	50*	0/2	No clinical or pathological findings.	125
	100*	0/2	No clinical or pathological findings.	
	125*	0/2	No clinical or pathological findings.	
	250	1/2	With doses of 250 mg/kg a deep depression, sporadic respiration, and death within 20 minutes; no pathological alterations.	
	500	1/1		
	1000	1/1		

TABLE VII (continued)

Test Compound	Dose (mg/kg)	Mortality (No. dead /total)	FINDINGS	Estimated Maximum Tolerated Dose (MTD) (mg/kg)
DET PA	396 500 637 1000	0/2 0/2 0/2 1/1	No clinical or pathological findings. Various degrees of depression; except at the 1000 mg/kg dosage, recovery was complete within 1 to 2 hours, no pathological alterations.	450
TET HA	500 1000 2000	0/2 1/1 1/1	Depression, sporadic respiration, recovery within 2 hours. Agitation, sporadic respiration, collapse; death within 30 minutes. Agitation; staggering gait; death within 5 minutes.	250
EG(AEE) TA	396 500 637 1000	0/2 1/2 1/2 1/1	No clinical or pathological findings. At dosages of 500 mg/kg and higher varying degrees of depression within 1 to 2 hours post treatment; no gross pathological lesions.	400
(HCH)ED TriA	500 1000 2000	0/2 1/1 1/1	Varying degrees of depression at all doses; at 1000 mg/kg dose death within 15 to 20 minutes post treatment; livers showed white-yellowish discoloration.	250
(AE)CHA TA	100* 200* 250* 500 1000 1260 1587 2000	0/2 0/2 0/2 0/2 0/1 1/1 1/1 1/1	No clinical or pathological symptoms. No clinical or pathological symptoms. At all doses, except the 250 mg/kg dose, various degrees of depression immediately after treatment lasted for 30 to 60 minutes; no gross lesions were found.	250

TABLE VII (continued)

Test Compound	Dose (mg/kg)	Mortality (No. dead /total)	FINDINGS	Estimated Maximum Tolerated Dose (MTD) (mg/kg)
(DCMACH)ED TriA	250*	0/2	No clinical or pathological symptoms.	500
	500*	0/2	No clinical or pathological symptoms.	
	1000	1/2	Deep depression immediately, collapse,	
	2000	1/2	death; no gross lesions.	
PG(AEE) TA	250	0/2	No clinical or pathological symptoms	250
	500	1/1	Dizziness, depression, circular movements; death after 12 minutes.	
	1000	1/1	Tonic spasms; death within 4 minutes; no gross lesions.	
2,3-BG(AEE) TA	250	0/2	No clinical symptoms.	250
	500	2/2	Depression; intermittent tonic spasms; death within 40 min.	
	637	2/2	Depression; death within 1 hour.	
	793	2/2	Depression; death within 1 hour.	
	1000	2/2	Depression; collapse; death within 20 minutes; no gross pathological lesions.	
1,4-BG(AEE) TA	100*	0/2	No clinical or pathological symptoms.	400
	200*	0/2	No clinical or pathological symptoms.	
	400*	0/2	No clinical or pathological symptoms.	
	500	0/2	Slight depression for 1 to 2 hours.	
	637	2/2	Depression; death within 10 to 14 hours.	
	793	2/2	Depression; collapse; death in 15 to 20 minutes.	
	1000	2/2	Depression; collapse; death within 10 minutes; no gross pathological lesions.	
TATEA HA	2000	0/2	No clinical symptoms; no pathological alterations.	2000

TABLE VII (continued)

Test Compound	Dose (mg/kg)	Mortality (No. dead /total)	FINDINGS	Estimated Maximum Tolerated Dose (MTD) (mg/kg)
TEPA HA	100*	0/2	No clinical symptoms.	400
	200*	0/2	No clinical symptoms.	
	400*	0/2	No clinical symptoms.	
	500	0/2	Slight depression; no gross lesions.	
	637	0/2	Tremors; depression for a few hours.	
	793	0/2	Tremors; depression for a few hours.	
	1000	1/2	Tremors; spastic respiration; depression; death after 12 hours; no gross pathological lesions.	

\* Tested with both free acid and calcium-sodium salt.



TABLE VIII

MORTALITY OF MALE RATS RECEIVING CHELATING AGENTS FOLLOWING  
ACUTELY TOXIC DOSES OF BERYLLIUM

Chelating Agent			Be <sup>++</sup> Dose (mg/kg)	Number of Animals	Mean Weight (g)	Percent Mortality at Day Post-Injection								
Compound	Dose (mg/kg)	Route of Admin- istration				0-1	1-2	2-3	3-4	4-5	5-6	6-7	7-14	Total
None	-	-	0.7	60	120 ± 18			10	30	30	20			90
	-	-	10.2	150	115 ± 15	54	46							100
ATA	100	i.p.	0.7	20	116 ± 13	5	15	15	5	5	5		5	55
	400	oral	0.7	10	121 ± 20	10			30	50				90
	150	i.p.	10.2	10	119 ± 8	70	30							100
SA	100	i.p.	0.7	10	121 ± 10	10	10	40			10	10		80
	200	i.p.	0.7	10	119 ± 11			30	40					70
	200	i.p.	10.2	10	117 ± 6	90	10							100
EDTA	200	i.p.	0.7	10	119 ± 10			10	70	20				100
	200	i.p.	10.2	10	119 ± 9	60	40							100
DAEE TA	100	i.p.	0.7	20**	118 ± 7			15	25	40	5			85
	125	i.p.	10.2	10	120 ± 6	90	10							100
DET PA	300	i.p.	0.7	10	115 ± 6			30	40					70
	400	i.p.	10.2	10	119 ± 9	40		50	10					100
TET HA	200	i.p.	0.7	10	118 ± 7			20	50	10	10			90
	250	i.p.	10.2	10	119 ± 5	70		30						100
EG(AEE)TA	300	i.p.	0.7	10	120 ± 8	10		50	30					90
	350	i.p.	10.2	10	119 ± 9	40	50	10						100
HCH(ED) TriA	200	i.p.	0.7	10	115 ± 7			50	40					100
	250	i.p.	10.2	10	120 ± 5	70	20	10						100

TABLE VIII (continued)

Chelating Agent			Be <sup>++</sup> Dose (mg/kg)	Route of Admin- istration	Number of Animals	Mean Weight (g)	Percent Mortality at Day Post-Injection							
Compound	Dose (mg/kg)	0-1					1-2	2-3	3-4	4-5	5-6	6-7	7-14	Total
(AE)CHA TA	200	i.p.	0.7	10	120 ± 8			20	50	20	10			100
	400	i.p.	0.7	20	118 ± 6		5		25	35				65
	350	oral	0.7	5	123 ± 8			20	20	60				100
	200	i.p.	10.2	10	117 ± 8	40	60							100
(DCMACH)ED TriA	500	i.p.	0.7	10	116 ± 7				90	10				100
	500	i.p.	10.2	10	117 ± 9	70	20	10						100
PG(AEE) TA	250	i.p.	10.2	10	117 ± 5	40	60							100
2,3-BG(AEE) TA	200	i.p.	10.2	10	118 ± 7	10	80	10						100
1,4-BG(AEE) TA	300	i.p.	0.7	10	118 ± 6		30	40	30					100
	400	i.p.	10.2	10	115 ± 9	20	70	10						100
TATEA HA*	200	i.p.	0.7	10	119 ± 6				40	20	10			70
	1000	i.p.	10.2	6	120 ± 3	100								100
TEPA HA	400	i.p.	0.7	10	120 ± 8			10	50	10				70
	400	i.p.	10.2	10	117 ± 5	60	40							100

\* insufficient material to administer higher doses.

\*\* Mean of two separate determinations.

TABLE IX

WEIGHT GAIN OF MALE RATS RECEIVING CHELATING AGENTS  
FOLLOWING ACUTELY TOXIC DOSES OF BERYLLIUM

<u>Treatment</u>	<u>Number of Animals</u>	<u>2-Week Weight Gain (g/rat)</u>
None	50	35.6
0.71 mg Be <sup>++</sup> ♦		
100 mg/kg ATA	9	6.8
200 mg/kg SA	3	11.7
400 mg/kg DAEE TA	2	16.0
400 mg/kg AE(CHA) TA	7	10.5
200 mg/kg TATEA HA	3	8.0
400 mg/kg TEPA HA	3	2.0
—	6	3.7

## SECTION IV

### CONCLUSIONS

None of the polyaminopolycarboxylic compounds were as effective as ATA in preventing the beryllium-induced mortality of male rats. The most effective compound, ATA, was active in both the in vitro system and the in vivo systems. The in vitro reversal of beryllium-induced inhibition of rat serum alkaline phosphatase appears to have merit as a preliminary exclusion screening test for compounds with potential in vivo activity; on the basis of this study, however, a compound which does not cause at least a 50% reversal of alkaline phosphatase inhibition will be of little value in preventing beryllium intoxication in rats.

## REFERENCES

1. White, M. R., Finkel, A. J., and Schubert, J., "Protection Against Experimental Beryllium Poisoning by Aurintricarboxylic Acid", J. Pharmacol. Exp. Therap. 102, 88 (1951).
2. Lindenbaum, A., White, M. R., and Schubert, J., "Studies on the Mechanism of Protection by Aurintricarboxylic Acid in Beryllium Poisoning. III. Correlation of Molecular Structure with Reversal of Biological Effects of Beryllium", Arch. Biochem. Biophys. 52, 110 (1954).
3. Lindenbaum, A., White, M. R., and Schubert, J., "Effect of Aurintricarboxylic Acid on Beryllium Inhibition of Alkaline Phosphatase", J. Biol. Chem. 196, 273 (1952).
4. Bodansky, A., "Notes on the Determination of Serum Inorganic Phosphate and Serum Phosphatase Activity", J. Biol. Chem. 120, 167 (1937).
5. DuBois, K. P., Cochran, K. W., and Mazur, M., "Inhibition of Phosphatases by Beryllium and Antagonism of the Inhibition by Manganese", Science 110, 420 (1949).
6. Fiske, C. H., and SubbaRow, Y., "The Colorimetric Determination of Phosphorus", J. Biol. Chem. 66, 375 (1925).
7. Litchfield, J. T., and Wilcoxon, F., "A Simplified Method of Evaluating Dose-Effect Experiments", J. Pharmacol. Exp. Therap. 96, 99 (1949).
8. Aldridge, W. N., Barnes, J. M., and Denz, F. A., "Experimental Beryllium Poisoning", Brit. J. Exp. Path. 30, 375 (1949).
9. Cochran, K. W., Zerwic, M. M., and DuBois, K. P., "Studies on the Mechanism of Acute Beryllium Poisoning", J. Pharmacol. Exp. Therap. 102, 165 (1951).
10. Schubert, J., and Lindenbaum, A., "Metal-Binding in Medicine", Sevin, M. J. Ed., p. 69, J. B. Lippincott Company, Philadelphia, Pa., (1960).

## DOCUMENT CONTROL DATA - R&amp;D

(Security classification of title, body of abstract and indexing annotation must be entered when the overall report is classified)

1. ORIGINATING ACTIVITY (Corporate author) International Bio-Research, Inc. 248 Rosemont Avenue St. Louis, Missouri 63119		2a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED	
		2b. GROUP N/A	
3. REPORT TITLE  SCREENING OF NEW CHELATING AGENTS FOR BERYLLIUM			
4. DESCRIPTIVE NOTES (Type of report and inclusive dates) Final report, June 1964 - March 1965			
5. AUTHOR(S) (Last name, first name, initial) Sternner, Wolfgang Loveless, L. E.			
6. REPORT DATE August 1965	7a. TOTAL NO. OF PAGES 22	7b. NO. OF REFS 10	
8a. CONTRACT OR GRANT NO. AF 33(615)-1804  b. PROJECT NO 6302  c. Task No. 630202  d.	9a. ORIGINATOR'S REPORT NUMBER(S)   9b. OTHER REPORT NO(S) (Any other numbers that may be assigned this report) AMRL-TR-65-135		
10. AVAILABILITY/LIMITATION NOTICES Qualified requesters may obtain copies of this report from DDC. Available, for sale to the public, from the Clearinghouse for Federal Scientific and Technical Information, CFSTI (formerly OTS), Sills Bldg, Springfield, Virginia 22151			
11. SUPPLEMENTARY NOTES		12. SPONSORING MILITARY ACTIVITY Aerospace Medical Research Laboratories, Aerospace Medical Division, Air Force Systems Command, Wright-Patterson AFB, Ohio	
13. ABSTRACT  Thirteen polyaminopolycarboxylic acid chelating agents were evaluated in vitro and in vivo as potential therapeutic agents for acute beryllium poisoning. In the in vitro test system the ability of the chelating agent to reverse beryllium induced inhibition of alkaline phosphate was measured. In the in vivo system, the chelating agent was evaluated by its ability to prevent mortality of rats that had received an acute lethal dose (LD <sub>50</sub> ) of beryllium sulfate. None of the polyaminopolycarboxylic acids reversed completely the inhibition of alkaline phosphatase at either 35 percent or 65 percent levels of inhibition. All compounds were ineffective in overcoming the toxic dose of beryllium in rats.			

Security Classification

14.	KEY WORDS	LINK A		LINK B		LINK C	
		ROLE	WT	ROLE	WT	ROLE	WT
	Physiology						
	Toxicity						
	Propellants						
	Metal poisoning						
	Beryllium						
	Phosphates (alkaline)						
	Vaccines						

**INSTRUCTIONS**

**1. ORIGINATING ACTIVITY:** Enter the name and address of the contractor, subcontractor, grantee, Department of Defense activity or other organization (*corporate author*) issuing the report.

**2a. REPORT SECURITY CLASSIFICATION:** Enter the overall security classification of the report. Indicate whether "Restricted Data" is included. Marking is to be in accordance with appropriate security regulations.

**2b. GROUP:** Automatic downgrading is specified in DoD Directive 5200.10 and Armed Forces Industrial Manual. Enter the group number. Also, when applicable, show that optional markings have been used for Group 3 and Group 4 as authorized.

**3. REPORT TITLE:** Enter the complete report title in all capital letters. Titles in all cases should be unclassified. If a meaningful title cannot be selected without classification, show title classification in all capitals in parenthesis immediately following the title.

**4. DESCRIPTIVE NOTES:** If appropriate, enter the type of report, e.g., interim, progress, summary, annual, or final. Give the inclusive dates when a specific reporting period is covered.

**5. AUTHOR(S):** Enter the name(s) of author(s) as shown on or in the report. Enter last name, first name, middle initial. If military, show rank and branch of service. The name of the principal author is an absolute minimum requirement.

**6. REPORT DATE:** Enter the date of the report as day, month, year; or month, year. If more than one date appears, on the report, use date of publication.

**7a. TOTAL NUMBER OF PAGES:** The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.

**7b. NUMBER OF REFERENCES:** Enter the total number of references cited in the report.

**8a. CONTRACT OR GRANT NUMBER:** If appropriate, enter the applicable number of the contract or grant under which the report was written.

**8b, 8c, & 8d. PROJECT NUMBER:** Enter the appropriate military department identification, such as project number, subproject number, system numbers, task number, etc.

**9a. ORIGINATOR'S REPORT NUMBER(S):** Enter the official report number by which the document will be identified and controlled by the originating activity. This number must be unique to this report.

**9b. OTHER REPORT NUMBER(S):** If the report has been assigned any other report numbers (*either by the originator or by the sponsor*), also enter this number(s).

**10. AVAILABILITY/LIMITATION NOTICES:** Enter any limitations on further dissemination of the report, other than those

imposed by security classification, using standard statements such as:

(1) "Qualified requesters may obtain copies of this report from DDC."

(2) "Foreign announcement and dissemination of this report by DDC is not authorized."

(3) "U. S. Government agencies may obtain copies of this report directly from DDC. Other qualified DDC users shall request through \_\_\_\_\_."

(4) "U. S. military agencies may obtain copies of this report directly from DDC. Other qualified users shall request through \_\_\_\_\_."

(5) "All distribution of this report is controlled. Qualified DDC users shall request through \_\_\_\_\_."

If the report has been furnished to the Office of Technical Services, Department of Commerce, for sale to the public, indicate this fact and enter the price, if known.

**11. SUPPLEMENTARY NOTES:** Use for additional explanatory notes.

**12. SPONSORING MILITARY ACTIVITY:** Enter the name of the departmental project office or laboratory sponsoring (*paying for*) the research and development. Include address.

**13. ABSTRACT:** Enter an abstract giving a brief and factual summary of the document indicative of the report, even though it may also appear elsewhere in the body of the technical report. If additional space is required, a continuation sheet shall be attached.

It is highly desirable that the abstract of classified reports be unclassified. Each paragraph of the abstract shall end with an indication of the military security classification of the information in the paragraph, represented as (TS), (S), (C), or (U).

There is no limitation on the length of the abstract. However, the suggested length is from 150 to 225 words.

**14. KEY WORDS:** Key words are technically meaningful terms or short phrases that characterize a report and may be used as index entries for cataloging the report. Key words must be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location, may be used as key words but will be followed by an indication of technical context. The assignment of links, rules, and weights is optional.